Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

Lifestyle can shape the composition of oral microbiome, study reveals

Lifestyle can shape the composition of beneficial bacteria and other microorganisms within the mouth, according to a new study led by Penn State biologists.

November 6, 2024

Boehringer Ingelheim once again turns to RNAi for new MASH therapies

Boehringer Ingelheim is partnering with China-based biotech Suzhou Ribo Life Science and its Sweden-based unit Ribocure Pharmaceuticals to develop siRNA therapies for metabolic dysfunction-associated steatohepatitis

January 4, 2024

HHS gives thumbs down to bluebird’s fertility support programme – Pharmaceutical Technology

Bluebird won approval with the FDA for its gene therapy Zynteglo (betibeglogene autotemcel) last year to treat beta thalassaemia. Credit: Gorodenkoff via Shutterstock. bluebird bio‘s

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.